BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
12.51
+0.05 (0.40%)
At close: Dec 16, 2025, 4:00 PM EST
12.76
+0.25 (2.00%)
After-hours: Dec 16, 2025, 5:03 PM EST
BioAge Labs Employees
As of December 31, 2024, BioAge Labs had 64 total employees, including 62 full-time and 2 part-time employees. The number of employees increased by 8 or 14.29% compared to the previous year.
Employees
64
Change (1Y)
8
Growth (1Y)
14.29%
Revenue / Employee
$92,453
Profits / Employee
-$1,184,234
Market Cap
448.55M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64 | 8 | 14.29% |
| Dec 31, 2023 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BIOA News
- 3 days ago - 2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Motley Fool
- 12 days ago - BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - GlobeNewsWire
- 21 days ago - BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - BioAge Labs to Present at Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 5 weeks ago - Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy - The Motley Fool
- 6 weeks ago - Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? - The Motley Fool
- 7 weeks ago - BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? - The Motley Fool
- 3 months ago - HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor - PRNewsWire